# FDA recall D-168-2013

> **Pacira Pharmaceuticals, Inc.** · Class II · drug recall initiated 2012-12-17.

## Product

EXPAREL (bupivacaine liposome injectable suspension),  1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA

## Reason for recall

Subpotent; bupivacaine

## Distribution

Nationwide distribution: AZ, DC, FL, GA, MA, NJ, NY, OH, and TX.

## Key facts

- **Recall number:** D-168-2013
- **Recalling firm:** Pacira Pharmaceuticals, Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2012-12-17
- **Report date:** 2013-03-06
- **Termination date:** 2013-05-03

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** San Diego, CA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-168-2013

## Citation

> AI Analytics. FDA recall D-168-2013. Retrieved 2026-05-25 from https://api.ai-analytics.org/recall/D-168-2013. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*